Timely work from @GavittWoodard & team! I think this fits with what many of us are seeing.
One question (among many) which our #radonc colleagues will ask is What dose of RT was used?
Unless risk of pneumonectomy, I’ve worked on teams that have used full definitive RT dose as neoadjuvant.
Do you think this makes a difference?
#tssmn
One question (among many) which our #radonc colleagues will ask is What dose of RT was used?
Unless risk of pneumonectomy, I’ve worked on teams that have used full definitive RT dose as neoadjuvant.
Do you think this makes a difference?
#tssmn
These are our real world data from Yale out now in @JTOonline comparing retrospective outcomes between patients treated with neoadj chemo-ICI to neoadj chemo (+/- XRT).View quoted post on X
Improved survival in the chemo-ICI cohort driven by pts with MPR and pCRs.